CYB004, or CYB-004, also known as deuterated dimethyltryptamine (dDMT), is a serotonergic psychedelic related to dimethyltryptamine (DMT) which is under development for the treatment of generalized anxiety disorder.[1][4][2][3] It is administered by inhalation or intravenous injection.[1][2]
| Clinical data | |
|---|---|
| Other names | CYB-004; Deuterated dimethyltryptamine; Deuterated DMT; dDMT |
| Routes of administration | Inhalation, intravenous[1][2] |
| Drug class | Serotonergic psychedelic; Serotonin receptor agonist[1][3] |
It is a tryptamine derivative and is a deuterated analogue and form of DMT.[1][4][3] The pharmacodynamic profile of CYB004, including its interactions with serotonin receptors and its effects in animals, is similar to that of DMT.[3] As with DMT, CYB004 is a potent agonist of the serotonin 5-HT2A receptor and produces psychedelic-like effects in animals.[1][5][3] However, CYB004, due to its deuteration, is more resistant to metabolism than DMT and shows a longer elimination half-life (by 2.5- to 2.9-fold) and slower clearance (by 38 to 55%) in animals.[3] The brain to plasma ratio of CYB004 was also increased (by 30%) relative to DMT, indicating slightly greater central permeability as well.[3]
As of August 2024, CYB004 is in phase 2 clinical trials for generalized anxiety disorder.[1][4] It was also under development for the treatment of substance-related disorders and of other psychiatric disorders, but development for these indications was discontinued.[1] The drug is under development by Cybin.[1][4] The exact chemical structure of CYB004 (i.e., which hydrogen atoms are deuterated) does not yet seem to have been disclosed.[1] However, Cybin patented deuterated tryptamines, including deuterated forms of DMT like DMT-d10, in 2023.[6] Other related drugs include the deuterated tryptamine CYB003 and the deuterated phenethylamines CYB005 and CYB210010.[5][2]
See also
editReferences
edit- ^ a b c d e f g h i j "CYB 004". AdisInsight. 14 August 2024. Retrieved 28 October 2024.
- ^ a b c d Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?". Nature Biotechnology. 42 (6): 827–830. doi:10.1038/s41587-024-02285-1. PMID 38831049.
- ^ a b c d e f g "ACNP 62nd Annual Meeting: Poster Abstracts P1 - P250". Neuropsychopharmacology. 48 (Suppl 1). Springer Science and Business Media LLC: 63–210. December 2023. doi:10.1038/s41386-023-01755-5. PMC 10729595. PMID 38040809.
- ^ a b c d "Delving into the Latest Updates on Deuterated dtryptamine with Synapse". Synapse. 27 October 2024. Retrieved 28 October 2024.
- ^ a b Cano GH, Dean J, Abreu SP, Rodríguez AH, Abbasi C, Hinson M, et al. (December 2022). "Key Characteristics and Development of Psychoceuticals: A Review". International Journal of Molecular Sciences. 23 (24): 15777. doi:10.3390/ijms232415777. PMC 9779201. PMID 36555419.
- ^ US 2023/0357147, Nivorozhkin A, Palfreyman M, "Deuterated tryptamine derivatives and methods of use", published 8 October 2024, assigned to Cybin IRL Ltd.